vaccin
one
success
accomplish
medic
scienc
diseas
preval
increasingli
rare
widespread
use
vaccin
next
clean
water
singl
intervent
overwhelm
effect
reduc
mortal
childhood
diseas
use
vaccin
smallpox
vaccin
erad
diseas
fatal
rate
two
decad
intens
effort
global
polio
erad
initi
approach
final
stage
aid
two
polio
vaccin
develop
jona
salk
albert
sabin
nevertheless
nextgener
vaccin
requir
combat
preval
diseas
import
field
develop
nextgener
vaccin
develop
vaccin
suitabl
mucos
immun
viral
bacteri
infect
start
mucos
surfac
thu
immun
infect
agent
may
depend
induct
mucos
immun
respons
result
certain
infecti
agent
mucos
rout
appropri
method
immun
report
induc
mucos
system
immun
respons
mucos
vaccin
achiev
via
number
rout
includ
oral
intranas
pulmonari
rectal
vagin
nasal
rout
straightforward
suitabl
vaccin
administr
advantag
disadvantag
nasal
vaccin
summar
tabl
prime
induct
site
mucos
immun
nasopharyng
tract
rodent
nasalassoci
lymphoid
tissu
nalt
nalt
consid
rodent
equival
waldey
ring
fig
lymphoid
tissu
tonsil
present
human
waldey
ring
form
protect
site
open
pharynx
provid
immun
protect
mucos
surfac
correl
secretori
immunoglobulina
siga
antibodi
alongsid
innat
defenc
mechan
provid
addit
protect
pathogen
murin
nalt
function
analogu
human
tonsil
anim
research
provid
insight
human
immunolog
studi
essenti
human
trial
vaccin
candid
howev
human
immun
biolog
composit
differ
anim
model
nasal
vaccin
develop
develop
appropri
vitro
model
provid
reproduc
approach
phenotyp
physiolog
featur
nalt
simul
techniqu
collect
analys
mucos
secret
cell
type
also
provid
ration
approach
evalu
vaccin
efficaci
nalt
compris
organis
structur
cell
involv
induct
immun
respons
includ
dendrit
cell
cell
b
cell
cover
epitheli
layer
cell
contain
distinct
cell
call
cell
cell
nalt
site
antigen
uptak
induct
mucos
immun
whilst
small
solubl
antigen
abl
penetr
nasal
epithelium
particul
antigen
mainli
taken
cell
nalt
antigen
activ
transport
cell
reach
dendrit
cell
macrophag
b
cell
process
present
consequ
activ
antigenspecif
helper
cell
th
cell
interact
b
cell
develop
iga
commit
iga
iga
b
cell
move
effector
site
nasal
passag
differenti
igaproduc
plasma
cell
secret
iga
dimer
dimer
iga
becom
siga
bind
polymer
ig
receptor
transport
iga
effector
site
overview
immun
respons
nalt
summar
fig
siga
abl
bind
toxin
bacteria
virus
neutral
activ
thu
prevent
entri
bodi
reach
intern
organ
whilst
prevent
infect
mucos
epithelium
certain
pathogen
group
streptococcu
concurr
infect
skin
advantag
vaccin
mucos
surfac
intranas
administr
induct
mucos
system
immun
respons
wherea
tradit
parenter
administr
gener
result
system
immun
respons
therefor
context
group
streptococcu
pathogen
concurr
infect
mucosa
system
site
ideal
vaccin
could
intranas
administ
vaccin
elicit
neutral
iga
prevent
colon
throat
system
igg
antibodi
facilit
clearanc
system
site
effect
vaccin
formul
intranas
deliveri
maintain
antigen
stabl
form
ensur
antigen
remain
nasopharyng
region
long
enough
antigen
interact
lymphat
system
stimul
immun
without
addit
provid
longterm
immun
review
discuss
lead
strategi
deliveri
system
adjuv
current
investig
develop
nasal
vaccin
nasal
deliv
influenza
vaccin
base
liveattenu
strain
current
investig
prevent
season
pandem
influenza
liveattenu
vaccin
advantag
mimick
natur
infect
present
influenza
antigen
nativ
conform
nasal
mucos
tissu
without
induc
flulik
symptom
exampl
type
vaccin
flumist
astrazeneca
first
nasal
trival
vaccin
season
influenza
compar
inject
trival
influenza
vaccin
flumist
vaccin
confer
longer
durat
protect
better
crossprotect
enhanc
efficaci
mucos
system
immun
despit
promis
liveattenu
influenza
vaccin
strategi
advers
side
effect
report
includ
safeti
concern
patient
allergi
asthma
well
irregular
side
effect
similar
bell
palsi
antigen
littl
affin
nasal
epithelium
tend
remov
quickli
mucociliari
clearanc
extend
nasal
resid
time
coadminist
antigen
mucoadhes
logic
approach
enhanc
absorpt
resid
time
facilit
interact
immun
system
signific
result
biodegrad
mucoadhes
polymer
carrier
highlight
use
mucos
vaccin
deliveri
polym
polylactidecoglycolid
plga
chitosan
algin
carbopol
explor
deliveri
antigen
via
intranas
rout
hydrophil
polym
like
sodium
algin
carbopol
absorb
mucu
form
hydrogen
bond
consequ
enhanc
nasal
resid
time
sodium
algin
linear
copolym
consist
acid
acid
residu
sodium
algin
biocompat
mucoadhes
use
control
deliveri
drug
follow
intranas
administr
vivo
studi
show
therapeut
efficaci
drugsodium
algin
formul
significantli
improv
comparison
nasal
administr
drug
alon
good
biocompat
low
cost
eas
prepar
major
advantag
use
algin
polym
deliveri
antigen
extens
use
sodium
algin
antigen
deliveri
system
improv
efficaci
mucos
immun
livestock
carri
exampl
induct
system
mucos
immun
respons
cattl
intranas
administr
antigen
algin
microspher
report
carbopol
crosslink
polyacryl
acid
polym
mixtur
starch
carbopol
use
carrier
influenza
viru
antigen
system
antigenspecif
igg
respons
induc
intranas
deliveri
level
igg
immun
respons
kinet
improv
presenc
carbopol
carbopol
use
experiment
deliveri
system
enhanc
adhes
mucos
surfac
may
facilit
enhanc
protect
peptid
protein
enzymat
degrad
carbopol
receiv
consider
attent
deliveri
protein
witschi
mrsni
show
use
bovin
serum
albumin
model
antigen
carbopol
gel
use
nasal
protein
deliveri
chitosan
nontox
linear
polysaccharid
produc
chitin
deacetyl
chitin
natur
occur
polym
found
exoskeleton
insect
crustacean
cation
polym
chitosan
interact
neg
charg
mucin
ionic
interact
mucociliari
clearanc
decreas
transient
effect
paracellular
transport
antigen
observ
addit
mucoadhes
chitosan
also
report
adjuv
properti
enhanc
humor
cellular
immun
respons
via
open
intercellular
tight
junction
favour
transport
antigen
combin
transient
open
tight
junction
mucoadhes
properti
like
enabl
interact
chitosanantigen
formul
interact
lymph
node
nasal
caviti
lead
improv
immunolog
respons
control
vaccin
releas
chitosan
nanoparticl
report
effect
taken
antigen
present
cell
induc
strong
mucos
system
immun
respons
antigen
chitosanbas
formul
use
improv
deliveri
immunogen
varieti
antigen
lutein
hormonereleas
hormon
lhrh
display
poor
immunogen
requir
presenc
adjuv
chitosanbas
formul
studi
potenti
adjuv
vaccin
lhrh
reduct
anim
steroidogenesi
spermatogenesi
observ
chitosan
use
adjuv
show
abil
deliveri
system
neutral
lhrh
influenza
matrix
protein
highli
conserv
form
basi
vaccin
mice
intranas
administ
chitosan
challeng
lethal
dose
virus
effect
crossprotect
influenza
viru
observ
vaccin
candid
result
show
chitosan
improv
efficaci
vaccin
alon
addit
nasal
immun
ntrimethyl
chitosan
tmc
base
nanoparticl
increas
nasal
resid
time
ovalbumin
model
antigen
intramucos
administr
slow
antigenreleas
tmc
nanoparticl
induc
detect
antibodi
titr
wherea
fast
antigenreleas
tmc
nanoparticl
show
high
siga
level
serum
antibodi
titr
found
nanoparticl
mucoadhes
stimul
matur
dendrit
cell
furthermor
formul
chitosan
dna
encod
viral
protein
coxsackieviru
shown
induc
high
level
mucos
siga
serum
igg
follow
intranas
challeng
lethal
signific
reduct
viral
load
observ
chitosan
report
slow
nasal
mucociliari
clearanc
prolong
contact
period
nalt
complex
exampl
chitosan
illustr
coadministr
antigen
mucoadhes
agent
enhanc
efficaci
potenti
reduc
antigen
dose
gener
facilit
develop
mucos
vaccin
deliveri
system
sinc
vaccin
alon
suffici
taken
mucos
administr
coadminist
penetr
enhanc
adjuv
encapsul
particl
variou
approach
overcom
immunogen
enhanc
properti
chitosan
due
combin
transient
open
tight
junction
mucoadhes
properti
make
promis
mucos
vaccin
deliveri
particul
deliveri
system
use
nasal
administr
vaccin
includ
liposom
immunestimul
complex
iscom
polymer
virosom
particul
antigen
use
transcellular
rout
reach
lymphoid
tissu
target
cell
cell
part
nalt
act
portal
entri
antigen
enter
region
contain
profession
antigen
present
cell
dendrit
cell
b
cell
cell
therebi
contribut
humor
cellular
immun
respons
particul
system
capac
present
multipl
copi
antigen
tend
similar
size
pathogen
mimick
natur
infect
liposom
particul
vesicl
compos
differ
ratio
lipid
cholesterol
enclos
aqueou
core
enabl
incorpor
wide
varieti
antigen
immunogen
confer
liposom
due
abil
accommod
multipl
copi
antigen
preferenti
uptak
macrophag
protect
within
biolog
environ
effect
intracellular
process
antigen
surfacemodifi
glycol
chitosan
oligomannos
coat
liposom
shown
elicit
humor
cellular
immun
respons
signific
compar
antigen
alon
follow
intranas
administr
surfac
charg
tend
influenc
immunogen
mucos
liposom
vaccin
formul
fusogen
liposom
encapsul
antigen
demonstr
effect
stimul
mucos
immun
respons
iscom
made
saponin
adjuv
along
lipid
antigen
gener
held
togeth
hydrophob
interact
constitu
essenti
compon
form
iscom
cholesterol
saponin
inher
particul
natur
multimer
antigen
present
potent
immunostimulatori
activ
make
iscom
attract
choic
vaccin
deliveri
sever
studi
shown
iscomincorpor
antigen
induc
specif
local
system
immun
respons
follow
intranas
administr
confer
protect
influenza
respiratori
syncyti
viru
hepat
b
virosom
altern
particul
deliveri
form
compos
extract
glycoprotein
viru
particl
mimic
viral
structur
viral
glycoprotein
present
virosom
high
affin
mucos
surfac
respiratori
tract
virosom
enabl
effici
induct
humor
cellular
respons
target
dendrit
cell
demonstr
effici
nasal
deliveri
system
sever
antigen
includ
dna
influenza
hiv
protein
particul
system
promis
nasal
deliveri
vaccin
enhanc
uptak
antigenpres
cell
confer
depot
effect
protect
antigen
degrad
research
physicochem
properti
particul
influenc
immunogen
contribut
develop
nasal
vaccin
deliveri
system
lipopeptid
bacteri
origin
synthet
deriv
repres
potent
immunostimul
given
combin
peptid
protein
antigen
exampl
lipid
moieti
includ
tripalmitoylsglyceryl
cystein
dipalmitoylsglyceryl
cystein
singlemultiplechain
palmit
acid
lipoamino
acid
laa
fig
desir
immunolog
activ
lipid
moieti
conjug
aris
intrins
adjuv
properti
b
cell
macrophag
activ
abil
induc
matur
dendrit
cell
promot
inflammatori
respons
gener
occur
via
signal
receptor
immun
system
recognis
lipid
moieti
pathogenassoci
molecular
pattern
lipopeptid
contain
evalu
develop
immunocontracept
vaccin
administ
intranas
construct
highli
immunogen
capabl
induc
high
titr
antibodi
effici
steril
femal
mice
administ
alon
salin
vaccin
streptococcu
pyogen
abil
induc
mucos
system
antibodi
follow
intranas
immun
confer
protect
bacteri
challeng
influenza
lipopeptid
shown
confer
protect
induc
longterm
cellular
respons
lipopeptid
vaccin
base
palmit
acid
moieti
may
present
ideal
strategi
pathogen
infect
mucos
surfac
intranas
administr
palmitoyl
lipopeptid
vaccin
human
cytomegaloviru
herp
viru
elicit
system
local
mucos
cellular
respons
administ
intranas
herp
simplex
viru
type
peptid
epitop
conjug
palmit
acid
moieti
shown
abil
prevent
transmiss
andor
limit
sever
diseas
librari
lipopeptid
vaccin
candid
compos
pyogen
b
cell
epitop
helper
epitop
lipid
moieti
base
laa
fig
also
investig
fig
orient
compon
lipopeptid
optim
elicit
strong
immun
respons
follow
intranas
immun
antibodi
titr
elicit
respons
lipopeptid
provid
import
inform
design
effect
lipopeptidebas
mucos
vaccin
interestingli
lipopeptid
selfadjuv
negat
use
addit
adjuv
could
easili
appli
peptidebas
vaccin
import
consider
lipopeptid
vaccin
ensur
lipid
moieti
easi
synthes
coupl
antigen
purifi
formul
result
laa
attract
option
synthes
coupl
peptid
antigen
use
standard
peptid
synthesi
method
lipopeptid
provid
sever
advantag
nasal
vaccin
develop
firstli
negat
requir
adjuv
potenti
induc
advers
side
effect
secondli
lipopeptid
vaccin
candid
induc
cellular
antibodi
respons
allow
control
desir
immun
respons
current
preclin
clinic
trial
lipopeptid
suggest
effect
nontox
synthes
use
current
method
peptid
synthesi
high
puriti
yield
lipopeptidebas
approach
nasal
deliveri
vaccin
induc
effect
mucos
system
immun
respons
dna
vaccin
investig
intranas
mucos
vaccin
develop
dnabas
vaccin
antibodi
rais
specif
protein
involv
immun
infect
shown
promis
anim
model
composit
neg
charg
dna
gener
hinder
entrap
effici
stabil
vaccin
formul
sever
investig
use
cation
compon
chitosan
polyethylenimin
pei
complex
dna
antigen
form
nanomicroparticl
intranas
deliveri
plasmid
dna
contain
chitosan
nanoparticl
nasal
immun
nucleocapsid
n
protein
sever
acut
respiratori
syndrom
coronaviru
sarscov
show
elicit
mucos
iga
well
system
igg
n
protein
sar
dna
vaccin
complex
cation
polym
effect
deliv
plasmid
dna
induc
antigenspecif
humor
cellular
immun
respons
pei
particular
interest
intranas
deliveri
due
report
manyfold
increas
gene
transfer
respiratori
tract
use
pei
formul
intranas
vaccin
dnaencod
influenza
antigen
high
level
antibodi
detect
bronchoalveolar
lavag
serum
cation
plga
particl
also
use
intranas
deliveri
system
administ
foot
mouth
diseas
fmdv
vaccin
encod
fmdv
capsid
protein
intranas
deliveri
cation
plga
particl
contain
fmdv
dna
vaccin
formul
enhanc
protect
immun
fmdv
whilst
dna
vaccin
shown
promis
intranas
vaccin
deliveri
technolog
requir
research
develop
effect
vaccin
improv
immunogen
antigen
use
adjuv
also
act
deliveri
system
ration
approach
vaccin
develop
nevertheless
achiev
potent
adjuv
effect
whilst
avoid
reactogen
toxic
major
challeng
peptid
protein
antigen
suffer
poor
immunogen
requir
use
adjuv
howev
exist
licens
adjuv
alum
lesser
extent
suitabl
adjuv
mucos
vaccin
administr
gener
induc
mucos
antibodi
unlik
system
immun
system
mucos
surfac
regularli
encount
extens
rang
foreign
materi
accommod
mucos
immun
system
must
select
respond
antigen
order
avoid
undesir
immun
respons
excess
activ
immun
system
thu
induct
mucos
immun
difficult
novel
strategi
critic
success
develop
mucos
adjuv
dendrit
cell
cell
major
cell
type
target
mucos
adjuv
cpg
oligodeoxynucleotid
cpg
odn
ligand
monophosphoryl
lipid
mla
repres
dendrit
cell
target
ligand
whilst
growth
factor
report
stimul
dendrit
cell
cpg
odn
mimic
immunostimulatori
effect
bacteri
dna
known
target
plasmacytoid
dendrit
cell
activ
matur
mucos
administr
cpg
odn
model
antigen
includ
influenza
viru
tetanu
toxoid
effect
elicit
antigenspecif
immun
furthermor
demonstr
safe
adjuv
nasal
dendrit
cell
target
properti
confer
protect
fatal
pneumococc
pneumonia
mice
end
cpg
odn
repres
mucos
dendrit
cell
target
adjuv
induct
antigenspecif
protect
mucos
immun
respons
bacteri
lipopolysaccharid
potent
immunostimulatori
agent
exhibit
extrem
toxic
chemic
modif
allevi
toxic
effect
result
identif
mla
fig
clinic
grade
mla
formul
correspond
main
activ
compon
corixa
mpl
adjuv
numer
preclin
clinic
studi
mpl
proven
potent
yet
nontox
adjuv
use
extens
adjuv
human
vaccin
trial
sever
infecti
diseas
cancer
effect
mpl
mucos
adjuv
investig
follow
intranas
administr
formul
mpl
ad
solubl
antigen
liposom
encapsul
antigen
liposom
antigen
formul
mpl
result
iga
respons
consist
higher
seen
mice
immun
liposom
antigen
free
antigen
without
mpl
result
demonstr
effect
mpl
adjuv
potenti
mucos
immun
respons
cell
provid
portal
entri
pathogen
invad
host
identif
molecul
requir
bacteri
viral
entri
cell
may
provid
ration
basi
develop
effect
mucos
adjuvantdeliveri
system
exampl
reovirus
initi
infect
cell
use
surfac
protein
celltarget
dna
vaccin
formul
consist
plasmid
dna
reoviru
induc
signific
mucos
system
immun
suggest
cell
target
could
use
approach
develop
mucos
vaccin
exampl
repres
sampl
strategi
could
use
facilit
develop
novel
mucos
adjuv
howev
mucos
adjuv
must
still
overcom
two
major
hurdl
effect
safeti
rel
difficult
object
compar
develop
vaccin
elicit
system
immun
due
uniqu
complex
mucos
immun
system
develop
novel
mucos
activ
intranas
administ
vaccin
potenti
provid
immun
myriad
infecti
diseas
mucos
administr
vaccin
present
ideal
strategi
mani
pathogen
infect
via
mucos
surfac
suitabl
combin
adjuv
target
cell
dendrit
cell
deliveri
system
mucoadhes
could
facilit
develop
effect
nasal
vaccin
use
noninvas
needlefre
nasal
rout
advantag
vaccin
programm
sinc
enhanc
patient
complianc
reduc
need
administ
specialis
healthcar
worker
